TX-LIVANOVA-PLC
9.3.2023 22:06:38 CET | Business Wire | Press release
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for the Essenz HLM from Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Additionally, LivaNova is initiating a broad commercial release in Europe, following a successful limited commercial release that supported more than 200 adult, pediatric and neonatal patients in Europe. The Essenz HLM and Essenz™ Patient Monitor comprise the Essenz™ Perfusion System, which enables a patient-tailored perfusion approach rooted in data-driven decisions that improve both clinical workflows and quality of patient care during cardiopulmonary bypass (CPB) procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005787/en/
LivaNova's Essenz™ Perfusion System (Photo: Business Wire)
“The Essenz Perfusion System has tremendous potential to become a key addition to our clinical practice, fusing a new era of technology with the skill and expertise of the perfusionist,” said Larry Garrison, Chief Perfusionist at Franciscan Health Indianapolis in Indianapolis, Indiana. “Since we participated in the Essenz HLM validations and the early release of the Essenz Patient Monitor, we’ve witnessed the System’s immense ability to unlock the potential of individualized care throughout all phases of CPB procedures.”
Essenz is based on 50 years of trusted partnership with perfusionists. LivaNova worked hand in hand with more than 300 perfusionists around the world who participated during every step of design and development to address their evolving needs in the operating room (OR), with an emphasis on patient safety and risk management.
Key attributes of the Essenz Perfusion System include:
Safe and Reliable:
The system is built on the proven LivaNova S5™ HLM, which has supported millions of patients for safe CPB procedures. Each pump on Essenz is controlled individually for simple, straightforward operations. HLM sensor checks confirm readiness before the CPB procedure starts. The Essenz HLM cockpit and Essenz Patient Monitor are connected but operate separately to further ensure reliability.
Patient-Tailored Care:
Accurate sensing technology and an intuitive dashboard on the Essenz Patient Monitor provide critical data to support individualized, data-driven patient care during a case. Essenz Patient Monitor utilizes official formulas to support perfusionists in the implementation of goal-directed perfusion (GDP), a therapy effective in reducing the risk of acute kidney injury.1 Mast-mounted pumps allow the user to optimize the position of the disposables (i.e., oxygenator and perfusion tubing set), which minimizes priming volumes and reduces hemodilution.
Intuitive:
The Essenz Patient Monitor offers an intuitive user interface and continuously records and displays data and events together to assist the perfusionist throughout a procedure. Data is automatically and seamlessly transferred, minimizing manual data entry and freeing up valuable time for the perfusionist in the OR. The technology platform is built to accommodate a stream of future software features and functionalities, making it a valuable long-term investment.
Flexible and Efficient:
The Essenz Perfusion System can be adapted to the individual needs of patients (adult and pediatric), workflows and users. It features an ergonomic design, including advanced cable management and a mast-mounted design that minimizes distractions and keeps the area clean and hygienic. The innovative cockpit provides one central view to control the device and check all perfusion and patient parameters. Also, Essenz has seamless integration with OR external devices and hospital information systems.
In addition, the Essenz Perfusion System is backed by a responsive service team of dedicated, local engineers in more than 100 countries, along with a global support center to address any needs.
“A perfusion system acts as a patient’s heart and lungs during an open-heart procedure, so having the highest-quality system backed by the expertise of a skilled perfusionist is paramount,” said Damien McDonald, Chief Executive Officer of LivaNova. “When we were designing Essenz, perfusionists told us they needed a system that gives them access to comprehensive data to drive more informed decision-making throughout the entire procedure. We’ve done that with Essenz. Through next-generation hardware and software, Essenz empowers perfusionists to better serve their patients with increasingly tailored care.”
Learn more about the entire Essenz Perfusion System on the LivaNova website.
*Note: The Essenz Heart-Lung Machine is not available for sale in all geographies. Visit the LivaNova website for important safety information.
References
-
Goal-Directed Perfusion to reduce Acute Kidney Injury: A Randomized Trial Ranucci M. et al.
J Thorac Cardiovasc Surg. 2018 Nov; 156(5): 1918-1927.e2. doi.org/10.1016/j.jtcvs.2018.04.045
About LivaNova
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Essenz Perfusion System, Essenz HLM and the Essenz Patient Monitor. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GIGABYTE Showcases Full-Stack AI Infrastructure from Rack-Scale Systems to Real-World Deployment at COMPUTEX 20261.6.2026 12:30:00 CEST | Press release
Following the introduction of its "Future Landing" vision, GIGABYTE Technology, a global leader in high-performance computing and AI infrastructure, brings that vision to life at COMPUTEX 2026 through a comprehensive showcase of systems, software, and real-world deployments that demonstrate how AI infrastructure is built, deployed, and operated at scale. From rack-scale AI factories and modular data centers to Physical AI workflows, clinical AI applications, and on-prem AI agents, GIGABYTE demonstrates how AI infrastructure moves beyond planning and into production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525486787/en/ Rack-Scale Infrastructure, Validated for AI Factories At the foundation of “Future Landing” is GIGABYTE’s expanding portfolio of rack-scale AI infrastructure designed for next-generation AI factories. Among the latest highlights is the NVIDIA Vera Rubin NVL72, showcased as part of GIGABYTE’s broader
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 20261.6.2026 12:00:00 CEST | Press release
Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal developmentCompany to host investor webcast showcasing momentum across solid tumor pipeline BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. Data from three differentiated BeOne pipeline assets will be presented, including: CDK4 inhibitor (BGB-43395) (poster presentation): First disclosure of anti-tumor activity in first-line (1L) HR+/HER2- metastatic breast cancer. B7-H4 ADC (BG‑C9074) (rapid oral presentation): Phase 1 dose-escalation and safety expansion data in adva
Electricity System Transformation Vital to Meet Future Needs, Arthur D. Little Blue Shift Report Finds1.6.2026 11:00:00 CEST | Press release
Arthur D. Little (ADL)’s Blue Shift Institute today published The Future of Electricity - From Building Capacity to Shaping Flexibility. The in-depth new report explores the growing pressures on electricity systems worldwide, and how they must transform to meet radically changing needs. With demand predicted to rise by 40-55% by 2035, it identifies practical strategies for maintaining reliability, affordability, and resilience. Electricity systems face profound challenges due to the accelerating electrification of end uses, increasing renewables deployments, and the digitalization of economies. Rising variability and system stress is already leading to instability, grid congestion, and disruption. Demonstrating this, an April 2025 blackout across the Iberian Peninsula led to at least eight deaths and an estimated US $1.8 billion in economic losses. Based on in-depth research and expert interviews, the report outlines the need to reshape infrastructure and operations to move from supply
Procore Redefines the Common Data Environment with Connected Data and Agentic AI1.6.2026 10:00:00 CEST | Press release
CDE unifies project data, workflows, BIM models, and asset information in one trusted environment—creating the foundation for AI agents to amplify the reach of construction teams Procore is the solution to fragmented data, helping ensure information integrity from approved design to handover Connects the full project lifecycle in one trusted environment with a single source of truth across BIM, Documents, Quality, and Assets Transforms BIM into a live execution workspace via BIM Model Manager, streaming models of any size directly to mobile devices to connect real-time project data with 3D coordination Leverages Procore AI with embedded Datagrid capabilities to turn project data into an actionable foundation, powering agentic AI coworkers that can help automate construction workflows and execute work directly within the platform Procore Technologies, Inc. (NYSE: PCOR), the leading global provider of construction management software, today announced the launch of its connected Common Da
AI Investment Boom Across the UK is Fuelled More by Fear of Missing out Than Actual Results, According to Expereo1.6.2026 10:00:00 CEST | Press release
Enterprises are investing aggressively in AI to avoid being left behind – but less than a quarter say AI implementations have exceeded expectations, often due to inadequate networks Enterprise AI spending is climbing rapidly, with boards racing to deploy the technology faster than they can measure whether it works. According to the latest IDC InfoBrief, commissioned by Expereo*, around 70% of organizations are investing in AI, motivated by its potential or by the fear of falling behind the competition, but they lag in disciplined ROI evaluation, and one in five (20%) admit they are investing aggressively in AI with little evaluation, driven by the fear of being left behind. The IDC InfoBrief, based on a survey of 800 technology leaders across Europe, the US, and APAC, found that AI has become one of the most prioritized technology investments globally. When asked which technologies their organization will prioritize in terms of effort and/or financial investment over the next 12 months
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom